In our 12 weeks trial carried out on participants with impaired FBG or mild T2D, we observed that CLM was able to effectively improve the serum levels of FBG, insulin, C-peptide, and HOMA index, with an optimal tolerability profile that is important to guarantee long-term compliance of the treatment on prediabetes or T2D. This evidence concerns the gene INS and prediabetes syndrome.